Skip to main content
Premium Trial:

Request an Annual Quote

MetaStat Laboratory Gets Massachusetts Licensure

NEW YORK (GenomeWeb) – MetaStat today said that it has received Massachusetts licensure for its digital pathology laboratory in Boston. 

The company, which provides tissue-based diagnostic tests for predicting cancer metastasis, can begin processing physician orders and run tissue samples from the majority of US states, the final major step to getting certification from the Centers for Medicare and Medicaid Services, it said. 

The Boston-based firm provides tests for breast, lung, colorectal, and prostate cancers. Its MetaSite Breast and MenaCalc assays are for stratifying patients based on their tumors' aggressiveness and the risk that their cancers will spread. Both tests are targeted for launch next year as prognostic tools for ER-positive, HER2-negative patients, the company recently told GenomeWeb.

The Scan

Cancer Survival Linked to Mutational Burden in Pan-Cancer Analysis

A pan-cancer paper appearing in JCO Precision Oncology suggests tumor mutation patterns provide clues for predicting cancer survival that are independent of other prognostic factors.

Australian Survey Points to Public Support for Genetic Risk Disclosure in Relatives of At-Risk Individuals

A survey in the European Journal of Human Genetics suggests most adult Australians are in favor of finding out if a relative tests positive for a medically actionable genetic variant.

Study Links Evolution of Stony Coral Skeleton to Bicarbonate Transporter Gene

A PNAS paper focuses on a skeleton-related bicarbonate transporter gene introduced to stony coral ancestors by tandem duplication.

Hormone-Based Gene Therapy to Sterilize Domestic Cat

A new paper in Nature Communication suggests that gene therapy could be a safer alternative to spaying domestic cats.